Impact of manufacturing procedures on CAR T cell functionality
N Watanabe, F Mo, MK McKenna - Frontiers in immunology, 2022 - frontiersin.org
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in
the past few decades. As of today, there are six CAR T cell products that have been …
the past few decades. As of today, there are six CAR T cell products that have been …
Scalable manufacturing of CAR T cells for cancer immunotherapy
M Abou-el-Enein, M Elsallab, SA Feldman… - Blood cancer …, 2021 - AACR
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
Expanding access to CAR T cell therapies through local manufacturing
M Elsallab, MV Maus - Nature biotechnology, 2023 - nature.com
Chimeric antigen receptor (CAR) T cells are changing the therapeutic landscape for
hematological malignancies. To date, all six CAR T cell products approved by the US Food …
hematological malignancies. To date, all six CAR T cell products approved by the US Food …
Recent advances and challenges in cancer immunotherapy
C Peterson, N Denlinger, Y Yang - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapy helps a person's immune system to target tumor cells.
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …
Recent advances in cancer immunotherapy, including immune checkpoint inhibition …
Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma
Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable
remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) …
remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) …
[HTML][HTML] Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
M Hiltensperger, AM Krackhardt - Frontiers in Immunology, 2023 - frontiersin.org
Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent …
immune-oncology pipeline over the last years. This is in great part due to the recent …
Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma
Anti-CD19 chimeric antigen receptor T (CAR-T) cells have demonstrated activity against
relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and immune effector cell …
relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and immune effector cell …
Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity
The antitumor efficacy of genetically engineered 'living drugs', including chimeric antigen
receptor and T-cell receptor T cells, is influenced by their activation, proliferation, inhibition …
receptor and T-cell receptor T cells, is influenced by their activation, proliferation, inhibition …
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating
adults and children with B-cell malignancies. Place-of-care manufacturing may improve …
adults and children with B-cell malignancies. Place-of-care manufacturing may improve …
[HTML][HTML] In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells
K Anthony-Gonda, A Ray, H Su, Y Wang, Y Xiong… - JCI insight, 2022 - ncbi.nlm.nih.gov
HIV-specific chimeric antigen receptor–T cell (CAR T cell) therapies are candidates to
functionally cure HIV infection in people with HIV (PWH) by eliminating reactivated HIV …
functionally cure HIV infection in people with HIV (PWH) by eliminating reactivated HIV …